WINDLASPharmaceuticals
Windlas Biotech Ltd — Profit & Loss Statement
₹736.75
-1.94%
Windlas Biotech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 1.41 Cr | 0.25 Cr |
| Tax Rate For Calcs | 0.24 | 0.25 | 0.25 | 0.16 |
| Normalized EBITDA | 112.13 Cr | 91.64 Cr | 64.59 Cr | 57.58 Cr |
| Total Unusual Items | 14.97 Cr | 10.83 Cr | 5.60 Cr | 1.55 Cr |
| Total Unusual Items Excluding Goodwill | 14.97 Cr | 10.83 Cr | 5.60 Cr | 1.55 Cr |
| Net Income From Continuing Operation Net Minority Interest | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Reconciled Depreciation | 27.98 Cr | 13.44 Cr | 12.36 Cr | 12.15 Cr |
| Reconciled Cost Of Revenue | 471.86 Cr | 396.18 Cr | 325.45 Cr | 302.82 Cr |
| EBITDA | 112.13 Cr | 91.64 Cr | 70.19 Cr | 59.13 Cr |
| EBIT | 84.14 Cr | 78.20 Cr | 57.83 Cr | 46.98 Cr |
| Net Interest Income | -4.38 Cr | -1.10 Cr | 2.70 Cr | 2.87 Cr |
| Interest Expense | 4.38 Cr | 1.10 Cr | 0.79 Cr | 1.42 Cr |
| Interest Income | 1.54 Cr | 1.97 Cr | 3.49 Cr | 4.29 Cr |
| Normalized Income | 60.99 Cr | 58.19 Cr | 38.44 Cr | 36.79 Cr |
| Net Income From Continuing And Discontinued Operation | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Total Expenses | 693.76 Cr | 566.23 Cr | 462.66 Cr | 422.78 Cr |
| Rent Expense Supplemental | 0.83 Cr | 0.48 Cr | 0.39 Cr | 0.44 Cr |
| Diluted Average Shares | 2.11 Cr | 2.09 Cr | 2.16 Cr | 2.05 Cr |
| Basic Average Shares | 2.09 Cr | 2.08 Cr | 2.16 Cr | 2.05 Cr |
| Diluted EPS | 28.87 | 27.88 | 19.70 | 18.58 |
| Basic EPS | 29.19 | 27.97 | 19.70 | 18.58 |
| Diluted NI Availto Com Stockholders | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Net Income Common Stockholders | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Minority Interests | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Including Noncontrolling Interests | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Net Income Continuous Operations | 60.99 Cr | 58.19 Cr | 42.63 Cr | 38.09 Cr |
| Tax Provision | 18.76 Cr | 18.90 Cr | 14.41 Cr | 7.48 Cr |
| Pretax Income | 79.76 Cr | 77.09 Cr | 57.04 Cr | 45.56 Cr |
| Other Non Operating Income Expenses | 18.02 Cr | 13.47 Cr | 0.43 Cr | 0.08 Cr |
| Special Income Charges | -0.11 Cr | 60000.00 | 0.81 Cr | -0.30 Cr |
| Other Special Charges | -90000.00 | -60000.00 | -0.88 Cr | -0.01 Cr |
| Write Off | 0.12 Cr | 0.00 | 0.06 Cr | 0.31 Cr |
| Net Non Operating Interest Income Expense | -4.38 Cr | -1.10 Cr | 2.70 Cr | 2.87 Cr |
| Interest Expense Non Operating | 4.38 Cr | 1.10 Cr | 0.79 Cr | 1.42 Cr |
| Interest Income Non Operating | 1.54 Cr | 1.97 Cr | 3.49 Cr | 4.29 Cr |
| Operating Income | 66.12 Cr | 64.73 Cr | 47.92 Cr | 40.59 Cr |
| Operating Expense | 221.90 Cr | 170.05 Cr | 137.21 Cr | 119.97 Cr |
| Other Operating Expenses | 71.00 Cr | 69.15 Cr | 28.91 Cr | 24.37 Cr |
| Depreciation And Amortization In Income Statement | 27.98 Cr | 13.44 Cr | 12.36 Cr | 12.15 Cr |
| Amortization | 1.10 Cr | 0.25 Cr | 0.20 Cr | 0.22 Cr |
| Depreciation Income Statement | 27.98 Cr | 13.44 Cr | 12.17 Cr | 11.93 Cr |
| Research And Development | 6.25 Cr | 7.88 Cr | 8.95 Cr | 6.51 Cr |
| Selling General And Administration | 24.51 Cr | 25.84 Cr | 18.61 Cr | 15.45 Cr |
| Selling And Marketing Expense | 21.33 Cr | 22.11 Cr | 14.60 Cr | 10.68 Cr |
| General And Administrative Expense | 3.18 Cr | 3.73 Cr | 4.01 Cr | 4.77 Cr |
| Rent And Landing Fees | 0.83 Cr | 0.48 Cr | 0.39 Cr | 0.44 Cr |
| Gross Profit | 288.02 Cr | 234.78 Cr | 185.13 Cr | 160.56 Cr |
| Cost Of Revenue | 471.86 Cr | 396.18 Cr | 325.45 Cr | 302.82 Cr |
| Total Revenue | 759.88 Cr | 630.96 Cr | 510.58 Cr | 463.37 Cr |
| Operating Revenue | 759.88 Cr | 630.96 Cr | 510.58 Cr | 463.37 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Windlas Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.